{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:48:17Z","timestamp":1791658097145,"version":"4.3.4"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":226,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.prdoa.2026.100496","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:18:53Z","timestamp":1787923133000},"page":"100496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Continuous subcutaneous foscarbidopa\/foslevodopa infusion as a therapeutic option in spinocerebellar ataxia type 8 presenting with early-onset parkinsonism"],"prefix":"10.1016","volume":"15","author":[{"given":"Francesco","family":"Onorati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Malfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyv","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Savica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2026.100496_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.107352","article-title":"A case of spinocerebellar ataxia type 8 with clinical manifestations as Parkinson\u2019s disease","volume":"135","author":"Wang","year":"2025","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2026.100496_bb0010","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3988\/jcn.2013.9.4.274","article-title":"Non-ataxic phenotypes of SCA8 mimicking amyotrophic lateral sclerosis and Parkinson disease","volume":"9","author":"Kim","year":"2013","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.prdoa.2026.100496_bb0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.17712\/nsj.2023.3.20230032","article-title":"Spinocerebellar ataxia type 8 presents as progressive supranuclear palsy","volume":"28","author":"Jiang","year":"2023","journal-title":"Neurosciences"},{"key":"10.1016\/j.prdoa.2026.100496_bb0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.parkreldis.2004.10.008","article-title":"Sporadic SCA8 mutation resembling corticobasal degeneration","volume":"11","author":"Baba","year":"2005","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2026.100496_bb0025","series-title":"GeneReviews(\u00ae)","article-title":"Spinocerebellar ataxia type 8","author":"Cleary","year":"1993"},{"key":"10.1016\/j.prdoa.2026.100496_bb0030","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"Soileau","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.prdoa.2026.100496_bb0035","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.parkreldis.2014.07.011","article-title":"Catechol-O-methyltransferase Val158Met polymorphism: modulation of wearing-off susceptibility in a Chinese cohort of Parkinson\u2019s disease","volume":"20","author":"Wu","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2026.100496_bb0040","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease","volume":"28","author":"Olanow","year":"2013","journal-title":"Mov. Disord."}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:48:55Z","timestamp":1791654535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112526000769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":8,"alternative-id":["S2590112526000769"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100496","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous subcutaneous foscarbidopa\/foslevodopa infusion as a therapeutic option in spinocerebellar ataxia type 8 presenting with early-onset parkinsonism","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100496","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100496"}}